What to do if an installation fails or a new installation is necessarry?I get the Message “The Installer was interrupted before RAIS could be installed. You need to restart the installer to try again”. What can I do?All my reports are empty with distorted icons. What is wrong?How can I see the log of deleted records?Can I use the preselected facility in Preselection filters?Installation of RAIS 3.2 Web failed on an upgraded SQL Server 2005 to SQL Server 2008 R2. What could be the reason? a>
I want the [Sources] field to display the serial number in addition to the source RAN. How can I customize the data appearing in a [Sources] field?How can I add a [Sources] field to a table?
Foremost, staff will be less exposed to radiation.
A The old installation must be completely cleaned up before a new installation. Use the RAIS installer to uninstall the old package. The uninstaller won’t delete the old database from the SQL Server, so if this database is no longer needed, it has to be deleted manually using SQL Server Management Studio. It is always recommended to have a backup of the database before deletion for the case that it contains data which could be needed later.
Page Top
While iridium 192 (192Ir) has many good qualities, different radionuclides are good for different
applications.
192Ir is a radionuclide with a high specific activity, or activity per unit mass, which means that a very
small source can provide a very high dose rate (HDR) – essential for HDR-applications. The picture shows some
typical dimensions for a HDR source of 192Ir . The effective photon energy of around 350 keV ensures a
sufficient absorbed dose at a sufficient distance from the source to treat the target homogeneously. A drawback,
however, is the short half-life of 74 days. This means that sources typically need to be replaced every three to four
months in order to maintain an acceptable treatment time. In typical low dose sate (LDR) -applications, size is of
somewhat less importance. An often-used radionuclide in gynaecological applications is caesium 137 (137Cs),
which has a much longer half-life (30.2 years) than 192Ir and, thus, only needs to be replaced every 10-15
years, while the specific activity is only a hundredth of that of 192Ir . For permanent implants, an
often-used source is iodine 125 (125I) due to its low photon energy making radiation absorbed within the
patient.
There is no such thing as a perfect radionuclide for all brachytherapy applications. One has to look at the
application in question and consider issues such as specific activity, half-life, type and energy of emission, and
shielding requirements.
Page Top
To ensure containment of the radioactive material and sometimes to act as a filter of unwanted radiation.
Brachytherapy sources are usually sealed so that the radioactive material is contained fully encapsulated within a
protective capsule. This capsule is designed to prevent leakage or escape of the radioactive source and it makes the
source rigid. Furthermore, for photon emitting sources, the capsule can serve the purpose of absorbing alpha and beta
rays produced through the source decay. A tiny brachytherapy seed (with a size roughly equivalent to a grain of rice)
such as radioactive iodine 125 (125I) in such a seed is encapsulated in titanium.
Page Top
No.
While HDR brachytherapy may offer advantages such as more practical procedures with outpatient treatment, increased
opportunities to optimize the absorbed dose and enhanced radiation protection of staff under normal conditions, there
are still other factors where LDR brachytherapy has an advantage. LDR can be said to be less technically complex than
HDR brachytherapy, where a large absorbed dose is given to the patient in a short time span. HDR treatment thus
requires more training and advanced knowledge in terms of operating the equipment and optimizing protection in the
treatment, including keeping the irradiating organs at risk to the minimum necessary to achieve the objective. While
the potential for error might not be greater for HDR brachytherapy, the consequences of HDR error might be exacerbated
due to the high activity of HDR brachytherapy sources.
Page Top
Yes, you should aim towards following international standards and codes of practice.
Over the years, there have been many different ways of specifying source strength in brachytherapy. Examples of
this: actual mass of radium, equivalent mass of radium, actual or apparent source activity in curie or bequerel,
air-kerma strength and reference air-kerma rate (RAKR) [Williamson and Nath]. Accidents
in brachytherapy have happened when source strength has been entered into a treatment planning system in units not
requested by the system and when sources of a certain activity have been ordered while sources of another activity have
been delivered with the same numerical of activity but other unit [IAEA Safety Reports Series No.
17].
In order to minimize the risk for this particular hazard, it is of value to strive towards meeting international
standards and codes of practice on how to specify source strength in brachytherapy, and what units to use [ICRU Reports 38 and 58]. This applies to both end-users and to manufacturers. While this is not yet
fully implemented internationally, care should be taken when specifying and verifying source strength.
References
- WILLIAMSON, J.F., NATH, R., Clinical implementation of AAPM Task Group 32 recommendations
on brachytherapy source strength specification, Med. Phys. 18 (1991) 439-448.
- INTERNATIONAL ATOMIC ENERGY AGENCY,Lessons Learned from
Accidental Exposures in Radiotherapy, IAEA Safety Reports Series No. 17, IAEA, Vienna (2000).
- INTERNATIONAL COMMISSION ON RADIATION UNITS AND MEASUREMENTS, Dose and Volume Specification
for Reporting Intracavitary Therapy in Gynecology, ICRU Report 38, ICRU, Bethesda, MD (1985).
- INTERNATIONAL COMMISSION ON RADIATION UNITS AND MEASUREMENTS, Dose and volume specification for reporting
interstitial therapy, ICRU Report 58, ICRU, Bethesda, MD (1997).
Page Top
Yes, this should be done as part of safe practice.
In order to monitor for excessive post-treatment radiation levels in the treatment room (potentially indicating a
source retraction failure), one of the most important safety measures is the use of radiation room monitor. In a fatal
accidental exposure related to HDR brachytherapy, it was reported [ICRP 97] that the radiation
room monitors had identified relatively high radiation level after treatment, but that these indications had been
ignored due to a previous history of monitor malfunction. There had been a failure of the weld between the transfer
wire and the source, which had left the source inside the patient. Had staff surveyed the patient with a portable
monitor after treatment, they would have been able to confirm that the radiation room monitor had been correct. With
both room monitors and portable monitors as part of the safety system, greater depth in the safety provisions is
created. There are also many other safety systems that should be in place in order to be able to conduct safe and
effective brachytherapy.
Page Top
Keep the step size constant within the centre.
When using stepping source remote afterloading technology, the dwell positions and dwell times are programmed so
that target coverage and organ at risk avoidance are optimized. The selection of step size, which determines the
distance between dwell positions, can vary, but it is recommended that in a particular centre the step size should be
kept at a particular constant value e.g. 5 or 10 mm (or another value, as long as it is kept constant within the
centre). The reason for this is that there are accident reports [ICRP 97] where steps have been
introduced in the programming with an incorrect length causing an undesired dose distribution. There are also reports
of dwell time data being introduced in reverse order, highlighting the necessity of independent check of this safety
critical data.
Page Top
References
- GERBAULET, A., et al. (Eds), The GEC ESTRO Handbook of Brachytherapy, European Society for Therapeutic Radiology
and Oncology (ESTRO), Brussels (2002).
- KUBO, H.D., GLASGOW, G.P., PETHEL, T.D., THOMADSEN, B.R., WILLIAMSON, J.F., High dose-rate brachytherapy treatment
delivery: Report of the AAPM Radiation Therapy Committee Task Group No. 59, Med. Phys. 25 (1998) 375-403.
Social Media
RPOP on Facebook
Copyright © 2013 International Atomic Energy Agency, Vienna International Centre, PO Box 100, 1400 Vienna, Austria